BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 2.8%

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s share price shot up 2.8% during trading on Wednesday . The company traded as high as $4.79 and last traded at $4.74. 1,078,536 shares traded hands during mid-day trading, a decline of 67% from the average session volume of 3,248,327 shares. The stock had previously closed at $4.61.

Analyst Ratings Changes

Separately, Needham & Company LLC restated a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Wednesday, April 10th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $13.29.

BioCryst Pharmaceuticals Stock Down 3.8 %

The stock has a market capitalization of $892.63 million, a PE ratio of -3.71 and a beta of 1.90. The company has a 50-day moving average of $5.24 and a 200 day moving average of $5.62.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The company had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $89.19 million. As a group, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.68 EPS for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

Large investors have recently made changes to their positions in the company. Fifth Third Bancorp grew its holdings in BioCryst Pharmaceuticals by 17,500.0% in the 3rd quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 3,500 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in BioCryst Pharmaceuticals by 96.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 2,388 shares in the last quarter. Fairfield Bush & CO. purchased a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at $34,000. State of Wyoming purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at $35,000. Finally, Advisory Services Network LLC grew its holdings in BioCryst Pharmaceuticals by 46.3% in the 1st quarter. Advisory Services Network LLC now owns 4,740 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 1,500 shares in the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.